SciSparc (NASDAQ:SPRC) Releases Earnings Results

SciSparc (NASDAQ:SPRC) issued its earnings results on Wednesday. The company reported ($4.85) EPS for the quarter, FiscalAI reports. The company had revenue of $0.14 million for the quarter.

SciSparc Stock Up 0.4%

Shares of NASDAQ:SPRC opened at $4.72 on Thursday. The company has a 50-day simple moving average of $5.94 and a 200-day simple moving average of $5.83. SciSparc has a one year low of $2.98 and a one year high of $54.63.

Analyst Ratings Changes

Several brokerages have recently weighed in on SPRC. Wall Street Zen raised SciSparc to a “hold” rating in a research report on Saturday, July 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SciSparc in a report on Friday, August 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

SciSparc Company Profile

SciSparc Ltd. (NASDAQ: SPRC) is an Israel-based specialty pharmaceutical company focused on developing therapies that combine cannabinoids with other pharmaceutical compounds. The company’s research programs are aimed at addressing conditions with significant unmet medical needs, including neurological and central nervous system disorders.

SciSparc has developed a pipeline that has included SCI-110, an investigational cannabinoid-based treatment being studied for conditions such as Tourette syndrome and Alzheimer’s disease-related agitation, and SCI-210, a combination therapy under development for autism spectrum disorder.